Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting

被引:13
|
作者
Townsend, Jeffrey P. [1 ,2 ,3 ,4 ,6 ]
Hassler, Hayley B. [1 ]
Dornburg, Alex [5 ]
机构
[1] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[2] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT USA
[3] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA
[4] Yale Univ, Program Microbiol, New Haven, CT USA
[5] Univ N Carolina, Dept Bioinformat & Genom, Charlotte, NC USA
[6] Yale Sch Publ Hlth, Dept Biostat, 135 Coll St, New Haven, CT 06510 USA
基金
美国国家科学基金会;
关键词
BNT162b2; mRNA-1273; mRNA vaccines; SARS-CoV-2 variant evolution; updated COVID-19 vaccine; vaccination schedule; ANTIBODY-RESPONSES; DURATION; COVID-19;
D O I
10.1002/jmv.28461
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
One of the most consequential unknowns of the COVID-19 pandemic is the frequency at which vaccine boosting provides sufficient protection from infection. We quantified the statistical likelihood of breakthrough infections over time following different boosting schedules with messenger RNA (mRNA)-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech). We integrated anti-Spike IgG antibody optical densities with profiles of the waning of antibodies and corresponding probabilities of infection associated with coronavirus endemic transmission. Projecting antibody levels over time given boosting every 6 months, 1, 1.5, 2, or 3 years yielded respective probabilities of fending off infection over a 6-year span of >93%, 75%, 55%, 40%, and 24% (mRNA-1273) and >89%, 69%, 49%, 36%, and 23% (BNT162b2). Delaying the administration of updated boosters has bleak repercussions. It increases the probability of individual infection by SARS-CoV-2, and correspondingly, ongoing disease spread, prevalence, morbidity, hospitalization, and mortality. Instituting regular, population-wide booster vaccination updated to predominant variants has the potential to substantially forestall-and with global, widespread uptake, eliminate-COVID-19.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] SARS-COV-2 MRNA vaccine-associated cutaneous vasculitis
    Erol, Vedat Bugra
    Can, Meryem
    NORTHERN CLINICS OF ISTANBUL, 2023, 10 (06) : 816 - 818
  • [2] Symptomatic SARS-CoV-2 Infection with Ageusia after Two mRNA Vaccine Doses
    Caponio, Vito Carlo Alberto
    Lipsi, Maria Rosaria
    Fortunato, Francesca
    Arena, Fabio
    Lo Muzio, Lorenzo
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (02)
  • [3] mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
    Jin, Yingqi
    Hou, Chen
    Li, Yonghao
    Zheng, Kang
    Wang, Chuan
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [4] mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
    Ilyichev, A. A.
    Orlova, L. A.
    Sharabrin, S., V
    Karpenko, L., I
    VAVILOVSKII ZHURNAL GENETIKI I SELEKTSII, 2020, 24 (07): : 802 - 807
  • [5] The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2
    Townsend, Jeffrey P.
    Hassler, Hayley B.
    Sah, Pratha
    Galvani, Alison P.
    Dornburg, Alex
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (31)
  • [6] SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients
    Basic-Jukic, Nikolina
    Ivo, Jelicic
    TRANSPLANT INFECTIOUS DISEASE, 2021,
  • [7] The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients
    Tolan, Nicole, V
    Sherman, Amy C.
    Zhou, Guohai
    Nabel, Katherine G.
    Desjardins, Michael
    Melanson, Stacy
    Kanjilal, Sanjat
    Moheed, Serina
    Kupelian, John
    Kaufman, Richard M.
    Ryan, Edward T.
    LaRocque, Regina C.
    Branda, John A.
    Dighe, Anand S.
    Abraham, Jonathan
    Baden, Lindsey R.
    Charles, Richelle C.
    Turbett, Sarah E.
    MICROBIOLOGY SPECTRUM, 2022, 10 (02):
  • [8] SARS-CoV-2 mRNA vaccine: Sometimes life needs a boost
    Lo, Carson Ka-Lok
    Kumar, Deepali
    TRANSPLANT INFECTIOUS DISEASE, 2023,
  • [9] Does the SARS-CoV-2 mRNA vaccine damage the ovarian reserve?
    Yildiz, Elif
    Timur, Burcu
    Guney, Gurhan
    Timur, Hakan
    MEDICINE, 2023, 102 (20) : E33824
  • [10] Orbital inflammatory disease following mRNA SARS-CoV-2 vaccine
    Grunenwald, Solange
    Lethellier, Gabriel
    Imbert, Philippe
    Dekeister, Celine
    Caron, Philippe
    CLINICAL CASE REPORTS, 2022, 10 (06):